Meloksam

Roman name

Meloxam

Pharmacokinetics

Well drawn from the blood. Permanent concentration in the serum achieved in 3-5 days after application. Kocentration in whey proportional to the dose. Prolonged drug use has no impact on the concentration in serum. Easily penetrate the joint fluid, reaching concentrations equal to the concentration in the plasma. Linking blood plasma proteins - 99%. Metabolised in the body, and only about 5% of the doses available in an unmodified form with faeces, and in trace quantities from urine. Metabolites are the same as the number of urine and faeces. Moderate renal and liver failure do not affect the kinetics PP. In patients older speed out from the body slightly reduced.

Farmakodinamika

Inside the present two forms : ziklooksigenaza-1 and ziklooksigenaza-2. Ziklooksigenaza-1 found in the different cells and the physiological functions : involved in the synthesis of GHG to protect the mucous membrane of the gastrointestinal tract and provide normal kidney bloodstream. Ziklooksigenaza-2 is a factor of support and inflammatory processes.

Indications

Distortive joint osteoarthritis, rheumatoid arthritis, ancylosing spondylitis (spinal disease).

Pregnancy and lactation

Contraindicated.

Contraindications

Гиперчувствительност ь (in other t.c.k NPVS); saying disease stomach and duodenal ulcers in the phase of deterioration and for a period of not less than six months after it; chronic kidney failure in patients with no exposure dializu; severe liver failure; Children age (up to 15 years); bleeding, including from the digestive tract bleeding in the boy's brain. pregnancy and breast feeding; allergic reaction (bronchial asthma, recurrent polyposis nose and okolonosovykh inflammation, swelling Kwinke, urticaria) at azetilsalicilovu acid and other NPVS.

Specific guidance

In the case of moderate renal insufficiency (Cl creatinine more than 25 ml / min), as well as moderate liver failure it is not necessary to reduce the dose of the drug.

Patient interaction

In appointing other NPVS, incl. acetylsalicylic acid, increases the risk of ulcers and bleeding from the digestive tract. Reduces the antigipertenziveh PP. In appointing the drug lithium can cause accumulation of lithium with the development of lithium intoxication (recommended monitoring of lithium concentration in the blood). Do gematotoksicnosti methotrexate (risk of anemia and radiation shows periodic monitoring of blood testing). In mochegonnami means can lead to the development of kidney failure. Can reduce the effectiveness of intrauterine contraception. Increases risk of bleeding in combination with antikoagulyantami (heparin), antiagregantami (tiklopidin) fibrinolitikami (streptokinase, fibrinolizin), a periodic monitoring of blood coagulability. The interaction with the oral gipoglikemicakimi means. Holestiramin accelerates removal from the body. Like other NPVS increases nefrotoksicnosti cyclosporine.

Precautions

To appoint caution : patients with the disorder ulcerated stomach virus, as well as patients receiving anticoagulants, and antiagreganta fibrinolitiki because bleeding from the upper gastrointestinal divisions, izgyazwlenia or perforation is not necessarily accompanied by a pronounced clinical symptoms; in older patients the bleeding can be fatalna; patients, in violation of funtion kidneys, a possible increase in these violations (this refers to the older patients, patients with congestive heart failure, cirrhosis, while lowering BCC after serious surgical interventions); in this case it is recommended to control diurez and biochemical indicators of kidney function, especially in the initial phase Terapii.u patients exposed dializu dose of the drug should not exceed 7.5 mg / Sut.pri any changes in the nasal lining or skin (itching, skin rashes, urticaria, Awareness photosensitive), consideration should be given for the lifting of a Preparata.pri side effects in the form of headache, dizziness, sleepiness, as well as visual impairment, it is necessary to give up driving and maintenance of vehicles and Mehanizmov.patienta hosting a mochegonne PP and meloxikam must take the fluid.

Storage conditions

List B. In a dry, the dark place at a temperature below 25 ° C

Shelf life

The registration

(OL)

The drug forms

Pill light-yellow, round, flat oboudostoronne, on the one hand the risk to the separation of pills. Surface tablets smooth, homogeneous, without stains and damage.

Directory → Nenarcoticeskie analgesics, including steroidal and противовоспалительны е means → Meloksam